Table 3.

Regulatory optimism for the future.

• CDER modernization of new drugs regulatory program

• Creation of new FDA Division of Hepatology and Nutrition (DHN)

• Recent examples of increased cooperation between new CDER review divisions

• FDA patient-focused drug development, incorporation of patients’ experiences, perspectives, needs and priorities into drug development and evaluation

• U.S. preventive services task force addressing nonalcoholic fatty liver disease

• Growing role and effectiveness of patient advocacy groups in liver disease